In:
Journal of the National Comprehensive Cancer Network, Harborside Press, LLC, Vol. 19, No. 11 ( 2021-11), p. 1218-1230
Kurzfassung:
In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody–drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1–mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.
Materialart:
Online-Ressource
ISSN:
1540-1405
,
1540-1413
DOI:
10.6004/jnccn.2021.0054
Sprache:
Unbekannt
Verlag:
Harborside Press, LLC
Publikationsdatum:
2021